Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0

作者：

Giri, Pratyush

Patil, Sushrut

Ratnasingam, Sumita

Prince, H. Miles

Milliken, Samuel

Meijide, Javier Briones

Coyle, Luke

Van der Poel, Marjolein

Mulroney, Carolyn M.

Farooqui, Mohammed Z. H.

Wong, Hansen

Desai, Rajendra

Zugmaier, Gerhard

Mergen, Noemi

Cannell, Paul

机构：

[1] Royal Adelaide Hosp, Adelaide, SA, Australia

[2] Alfred Hosp & Monash Univ, Melbourne, Vic, Australia

[3] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[4] Epworth Healthcare, East Melbourne, Australia

[5] Sir Peter MacCallum Canc Inst, East Melbourne, Australia

[6] St Vincents Hosp, Darlinghurst, NSW, Australia

[7] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[8] Royal Northshore Hosp, St Leonards, NSW, Australia

[9] Maastricht Univ, GROW Sch Oncol & Dev Biol, Div Hematol, Dept Internal Med,Med Ctr, Maastricht, Netherlands

[10] Univ Calif San Diego, La Jolla, CA USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Amgen Clin Pharmacol Modeling & Simulat, South San Francisco, CA USA

[13] IQVIA Inc, Biostat Sci, Mumbai, India

[14] Amgen Res Munich GmbH, Munich, Germany

[15] Royal Perth Hosp, Dept Med, Perth, WA, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

19584

引用

页数：1

共 50 条

[31] y Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Jaeger, Ulrich
Worel, Nina
McGuirk, Joseph P.
Riedell, Peter A.
Fleury, Isabelle
Borchmann, Peter
Chu, Jufen
Abdelhady, Ahmed M.
Forcina, Alessandra
Pacaud, Lida Bubuteishvili
Waller, Edmund K.
BLOOD, 2019, 134
[32] Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
Sanchez, Pilar Martinez
Zugmaier, Gerhard
Gordon, Paul
Jabbour, Elias
Roca, Jose J. Rifon
Schwartz, Stefan
Borlenghi, Erika
Huguet, Francoise
Hernandez-Rivas, Jesus Maria
Lussana, Federico
Berthon, Celine
Kadu, Priti
Wong, Hansen
Markovic, Ana
Katlinskaya, Yuliya
Rambaldi, Alessandro
BLOOD, 2022, 140 : 6122 - 6124
[33] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Viardot, A.
Goebeler, M.
Pfreundschuh, M.
Adrian, N.
Libicher, M.
Hess, G.
Zettl, F.
Neumann, S.
Degenhard, E.
Stieglmaier, J.
Zhang, A.
Nagorsen, D.
Bargou, R. C.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
[34] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Balari, Anna Sureda
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[35] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
Mueller, Karen Thudium
Grupp, Stephan A.
Maude, Shannon L.
Levine, John E.
Pulsipher, Michael
Boyer, Michael W.
August, Keith Jason
Myers, Gary Douglas
Awasthi, Rakesh
Waldron, Edward K.
Bubuteishvili-Pacaud, Lida
Taran, Tanya
Cota, Mariana
Tam, Constantine Si Lun
Jager, Ulrich
Foley, Ronan
Borchmann, Peter
Schuster, Stephen J.
Waller, Edmund K.
Laetsch, Theodore Willis
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Ozcan, Muhit
Lee, Seung Tae
Mensah, Felix
Modi, Dipenkumar
Fossa, Alexander
Kim, Won Seog
Paszkiewicz-Kozik, Ewa
Sawalha, Yazeed
Sevindik, Omur Gokmen
Norasetthada, Lalita
Santoro, Armando
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
Lavie, David
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
Martin Garcia-Sancho, A.
Baile, M.
Rodriguez, G.
Dlouhy, I.
Sancho, J. M.
Jarque, I.
Gonzalez-Barca, E.
Salar, A.
Espeso, M.
Grande, C.
Bergua, J.
Montes-Moreno, S.
Redondo, A.
Enjuanes, A.
Campo, E.
Lopez-Guillermo, A.
Caballero, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
[38] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
Longcor, J.
Oliver, K.
Friend, J.
Callandar, N.
ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
[39] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
Peters, Anthea
Nowakowski, Grzegorz S.
Dabas, Rosy
Amoloja, Theresa
Xue, Zhenyi
Koch, Caroline
Waltl, Eva E.
Fleury, Isabelle
BLOOD, 2022, 140 : 3811 - 3813
[40] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Maria Jose
Schuster, Stephen J.
Salles, Gilles
Maziarz, Richard T.
Anak, Ozlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →